Roger Lassing

Corporate Officer/Principal presso ICONOVO AB

59 anni

Health Technology

Commercial Services

Consumer Services

Profilo

Roger Lassing is currently the Vice President of Business Development at Iconovo AB.
Previously, he held positions as Vice President at Takeda Pharmaceutical Co., Ltd., Vice President & Global Brand Manager at AstraZeneca AB, and Senior Manager of Global Business Development at LEO Pharma AB.
Lassing received his undergraduate degree and MBA from the University of Lund.

Posizioni attive di Roger Lassing

Società	Posizione	Inizio
ICONOVO AB	Corporate Officer/Principal	01/01/2019

Tutte le posizioni attive di Roger Lassing

Precedenti posizioni note di Roger Lassing

Società	Posizione	Fine
LEO Pharma AB	Corporate Officer/Principal	-
TAKEDA PHARMACEUTICAL COMPANY LIMITED	Corporate Officer/Principal	-
AstraZeneca AB AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden.	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di Roger Lassing

Formazione di Roger Lassing

University of Lund

Masters Business Admin

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Roger Lassing

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	2
ICONOVO AB	Health Technology
TAKEDA PHARMACEUTICAL COMPANY LIMITED	Health Technology

Aziende private	2
AstraZeneca AB AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden.	Commercial Services
LEO Pharma AB